Journals / Akademik Gastroenteroloji Dergisi / 2022 / Cilt: 21 - Sayı: 3

Assessment of metabolic and inflammatory risk factors in patients with colorectal adenoma and carcinoma

Kolorektal adenoma ve karsinomlu hastalarda metabolik ve inflamatuvar risk faktörlerinin değerlendirilmesi

Pages
115–125
Publication Date
2022-12-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Metabolic syndrome, severe liver steatosis, and inflammatory process may be risk factors for the transition from colon adenoma to adenocarcinoma and shorter survival in colorectal cancer patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Aims: Metabolic syndrome and its related components are thought to be risk factors for developing colorectal neoplasms due to hyperinsulinemia, insulin resistance, and oxidative stress resulting in chronic low-grade inflammation.
📊
Key Findings & Data:Materials and Methods: Data of 151 patients diagnosed with colon adenoma and colorectal adenocarcinoma were retrospectively reviewed.
💡
Conclusion & Impact:Conclusions: Metabolic syndrome, severe liver steatosis, and inflammatory process may be risk factors for the transition from colon adenoma to adenocarcinoma and shorter survival in colorectal cancer patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Kolorektal adenom · kolorektal adenokanser · insulin direnci

Abstract

Background and Aims: Metabolic syndrome and its related components are thought to be risk factors for developing colorectal neoplasms due to hyperinsulinemia, insulin resistance, and oxidative stress resulting in chronic low-grade inflammation. This study aims to explain the association of colorectal neoplasms (colon adenocarcinoma and colon adenoma) with metabolic syndrome components, non-alcoholic fatty liver disease, and inflammatory markers. Materials and Methods: Data of 151 patients diagnosed with colon adenoma and colorectal adenocarcinoma were retrospectively reviewed. Demographic characteristics, routine blood tests, colonoscopic findings, pathology results, tumor-node-metastasis stages of colorectal adenocancer, and hepatic ultrasonography findings were recorded. The Homeostatic Model Assessment for Insulin Resistance scores were calculated. Results: The study cohort consisted of 71 patients with adenoma and 80 patients with colorectal adenocancer. The number of patients with diabetes mellitus, hypertension, hypertriglyceridemia, metabolic syndrome, severe liver steatosis was significantly higher in the colorectal adenocancer group compared to the colorectal adenoma group. Additionally, neutrophil-lymphocyte ratio, C-reactive protein, and C-reactive protein to albumin ratio were significantly higher in the colorectal adenocancer group compared to the adenoma group. In univariant analysis, patients with diabetes mellitus, hypertension, hypertriglyceridemia, metabolic syndrome, severe liver steatosis were found to have a shorter duration of survival than those who did not have these risk factors. In multivariate analysis, advanced tumor-node-metastasis stage, severe hepatosteatosis, hypertension, and hypertriglyceridemia were found to be independent risk factors for survival of the patients with colorectal adenocancer. Conclusions: Metabolic syndrome, severe liver steatosis, and inflammatory process may be risk factors for the transition from colon adenoma to adenocarcinoma and shorter survival in colorectal cancer patients.

Özet

Giriş ve Amaç: Metabolik sendrom ve ilişkili bileşenlerinin, hiperinsülinemi, insülin direnci ve kronik düşük dereceli inflamasyonla sonuçlanan oksidatif strese bağlı kolorektal neoplazmların gelişimi için risk faktörleri olduğu düşünülmektedir. Bu çalışma, kolorektal neoplazmların (kolon adenokarsinom ve kolon adenomu) metabolik sendrom bileşenleri, non-alkolik yağlı karaciğer hastalığı ve inflamatuvar belirteçlerle ilişkisini açıklamayı amaçlamaktadır. Gereç ve Yöntem: Kolon adenoma ve kolorektal adenokarsinom tanısı alan 151 hastanın verileri geriye dönük olarak incelendi. Demografik özellikler, rutin kan tetkikleri, kolonoskopik bulgular, patoloji sonuçları, kolorektal kanserin tümör-lenf nodu-metastaz evreleri ve hepatik ultrasonografi bulguları kaydedildi. İnsülin direnç testi skorları hesaplandı. Bulgular: Çalışma kohortu, kolorektal adenoma olan 71 hasta ve kolorektal kanseri olan 80 hastadan oluşuyordu. Diabetes mellitus, hipertansiyon, hipertrigliseridemi, metabolik sendrom, şiddetli karaciğer yağlanması olan hasta sayısı adenoma grubuna göre kolorektal kanser grubunda anlamlı olarak daha yüksekti. Ek olarak, nötrofil-lenfosit oranı, C-reaktif protein ve C-reaktif protein/albümin oranı, kolorektal adenoma grubuna göre, kolorektal kanser grubunda anlamlı olarak daha yüksekti. Tek değişkenli analizde diabetes mellitus, hipertansiyon, hipertrigliseridemi, metabolik sendrom, şiddetli karaciğer steatozu olan hastaların, bu risk faktörlerine sahip olmayanlara göre daha kısa sağkalım süresine sahip oldukları bulundu. Çok değişkenli analizde, ileri tümör-lenf nodu-metastaz evresi, şiddetli hepatosteatoz, hipertansiyon ve hipertrigliseridemi, kolorektal adenokanserli hastaların sağkalımı için bağımsız risk faktörleri olarak bulundu. Sonuç: Metabolik sendrom, ciddi karaciğer yağlanması ve inflamatuvar süreç, kolorektal kanser hastalarında, kolon adenomundan adenokarsinoma geçiş ve daha kısa sağkalım için risk faktörleri olabilir.

🔖

Cite This Article

KARAHAN, E., SARGIN, Z. G., ÜSTÜNDAĞ, Y. (2022). Assessment of metabolic and inflammatory risk factors in patients with colorectal adenoma and carcinoma. Akademik Gastroenteroloji Dergisi, Cilt: 21 - Sayı: 3, 115–125. https://ajindex.com/articles/865807

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108
  2. Lin X, You F, Liu H, et al. Site-specific risk of colorectal neoplasms in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PloS One 2021;16:e0245921
  3. Zhu B, Wu X, Wu B, et al. The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on cohort studies. PLoS One 2017;12:e0176068
  4. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
  5. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatoryissue. Ann N Y Acad Sci 2011;1229:45-52
  6. Jinjuvadia R, Lohia P, Jinjuvadia C, Montoya S, Liangpunsakul S. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol 2013;47:33-44
  7. Bowers K, Albanes D, Limburg P, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 2006;164:652-64
  8. Stocks T, Lukanova A, Bjørge T,et al; Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2011;117:2398-407
  9. Tsilidis KK, Brancati FL, Pollak MN, et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2010;21:1-10
  10. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: The European prospective investigation into cancer and nutrition study. Cancer Prev Res 2011;4:1873-83
  11. Ferraioli G, Monteiro LBS. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 2019;25:6053-62
  12. Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2016;65:1080-6
  13. Becker DJ, Iyengar AD, Punekar SR, et al. Diabetes mellitus and colorectal carcinoma outcomes: a meta-analysis. Int J Colorectal Dis 2020;35:1989-99
  14. Wu L, Yu C, Jiang